Kornimate/medical-research-clean huggingface dataset:
9mw2821 combined with toripalimab injection in subjects with local advanced or metastatic urothelial cancer

Conditions: Advanced Urothelial Carcinoma

Summary: this is a phase ib/ii, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9mw2821 combined with toripalimab injection in subjects with local advanced or metastatic urothelial cancer.


Eligibility criteria:
inclusion criteria: * sign and date the informed consent form e approved by independent ethics committe. * male or female subjects aged 18 to 80 years (including 18 and 80 years). * ecog status of 0 or 1. * histologically or cytologically confirmed local advanced or metastatic urothelial cancer * subjects have received at least 1 line advanced standard therapy or were not treated before * subjects must submit tumor tissues for test * life expectancy of ≥ 12 weeks. * subjects must have measurable lesions according to recist (version 1.1). * adequate organ functions * sexually active fertile subjects, and their partners, must agree to use methods of contraception during the study and at least 6 months after termination of study therapy. * subjects are willing to follow study procedures. exclusion criteria: * anti-tumor treatment such as chemotherapy and radiotherapy within 21 days prior to the first dose of study drug. * major surgery within 28 days prior to first dose of study drug. * pd-1/pd-l1/pd-l2 inhibitors used in the previous treatment for la/m uc. * previous treatment with adcs conjugated with mmae payload. * clinical significantly toxicity grade ≥ 2 (except alopecia and pigmentation) related to previous treatment. * peripheral neuropathy grade ≥ 2. * poorly controlled blood sugar. * increased risks of corneal disease assessed by the investigator prior to the first dose of study drug. * documented history of clinically significant cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug. * active infections, such as uncontrolled hbv/hcv/hiv/tb infection, etc. * other serious or uncontrolled diseases, such as serious interstitial pneumonia/asthma, serious thromboembolic events, etc. * poorly controlled central nervous system metastases. * organ transplantation or allogeneic hematopoietic stem cell transplantation in the past. * history of drug abuse or mental illness. * known allergic sensitivity to any of the ingredients of the study drug. * any p-glycoprotein (p-gp) inducers/inhibitors or potent cyp3a4 inducers/inhibitors within 14 days prior to the first dose of study drug. * history of autoimmune disease requiring systemic treatment within 2 years before the first dose. * any live vaccines within 4 weeks before first dose of study drug or during the study. * use of any investigational drug or medical instruments within 28 days prior to the first dose of study drug. * history of another malignancy within 3 years before the first dose of study drug. subjects with curable malignancies are allowed. * other conditions unsuitable into the study.
outcomes of cpm usage following arthroscopic acetabular labral repair

Conditions: Femoro Acetabular Impingement; Pain, Postoperative; Hip Labral Tear

Summary: the purpose of this study is to measure whether cpm (continuous passive motion) usage improves outcomes following arthroscopic hip surgery that includes labral repair. investigators tested the hypothesis that cpm usage reduces pain levels and pain medication use and improves function in individuals who undergo hip arthroscopy.

subjects undergoing primary hip arthroscopy for acetabular labral repair were randomized to determine whether they would receive a cpm. those subjects receiving a cpm were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks. the total number of pain medications and average pain scores over the two weeks, as well as hip outcome score activity of daily living (hos adl) scores at standard time points were compared via a two sample t-test and intention-to-treat analysis.

Eligibility criteria:
inclusion criteria: * undergoing hip arthroscopy to repair a torn labrum exclusion criteria: * pregnancy * revision surgery * bilateral surgery

Keywords: continuous passive motion device hos-adl hip arthroscopy
ischemia-reperfusion injury model on healthy volunteers and measurement of oxidative and inflammatory markers

Conditions: Ischemia-reperfusion Injury

Summary: oxygen is necessary for the survival of oxygen consuming organisms. but the organisms metabolism alter the oxygen to free radicals. free radicals are molecules which due to their structure can react with other molecules resulting in cell damage. this damage is due to several mechanisms. this is e.g what happens when human tissue is cut of from blood supply for a time, and the blood supply is again restored. the damage following the restoration of blood is known as "ischemia-reperfusion injury". the reopening of the vessels and thereby supplying oxygenated blood to the deprived tissue can in it self contribute to cell death due to excessive amounts of free radicals. antioxidants can neutralize free radicals and thereby minimize their damage. the purpose of the investigators methodology study is to make an ischemia-reperfusion model on healthy volunteers (on the lower limb) to examine the expression of markers that are expressed in the muscle and the blood when blood supply is cut of to an area and later restored. the investigators wish to measure the product of the damage caused by free radicals and the levels of antioxidants. if the investigators can produce elevation of oxidative and inflammatory markers, this model can be used to test antioxidative intervention.


Eligibility criteria:
inclusion criteria: * male * between 18 and 40 years. * non smokers. * no known history of familiar cardio/vascular diseases. * no intake of prescription medicine.

Keywords: ischemia-reperfusion injury oxidative markers inflammatory markers
intratumoral can1012(selective tlr7 agonist) in subjects with solid tumors

Conditions: Solid Tumor; Cancer Metastatic

Summary: to evaluate can1012(selective tlr7 agonist) when administered by it injection to subjects with advanced solid tumors who are not candidates for standard therapy.

this is a phase 1, open-label, first-in-human, single-arm, multicenter, dose escalation study of it can1012 in subjects with advanced solid tumors who are not candidates for standard therapy. subjects will be enrolled in cohorts of 3 at each dose level using a 3+3 dose escalation design approach.

Eligibility criteria:
inclusion criteria: 1. able and willing to provide written informed consent and willing to comply with the study's requirements. 2. male or female age \>18 years at screening. 3. metastatic or locally advanced solid tumor that has progressed on, is refractory to, or for which there is no efficacious standard of care therapy. 4. demonstrate adequate organ function as defined below. all screening laboratory assessments should be performed within 14 days of treatment initiation. 5. performance status of 0 or 1 on the ecog performance scale. 6. life expectancy \>12 weeks at baseline. 7. women of childbearing potential must have negative serum pregnancy test within 3 days prior to receiving the first study drug administration. 8. for women of childbearing potential, must be willing to use an adequate method of contraception from 30 days prior to the first study drug administration and 120 days following last day of study drug administration. 9. male subjects of childbearing potential must be surgically sterile or must agree to use adequate method of contraception during the study and at least 120 days following the last day of study drug administration. exclusion criteria: 1. received prior tlr7/8 agonists (excluding topical agents). 2. has untreated or uncontrolled central nervous system (cns) involvement. 3. will receive concurrent chemotherapy, immunotherapy, biologic, hormonal therapy, or other therapies for cancer. 4. received systemic interferon alfa (ifnα) prior to enrollment. 5. unresolved toxicities from prior therapy, defined as having not resolved to ctcae v5.0 grade 0 or 1, with exception of endocrinopathies from prior therapy, alopecia, and vitiligo. 6. treatment with systemic corticosteroids. 7. concomitant or planned use of sensitive substrates of major cytochrome p450 enzymes. 8. has an active infection requiring systemic therapy. 9. has known active infection with the human immunodeficiency virus, 10. unstable/inadequate cardiac function. 11. uncontrolled concurrent illness. 12. a history of interstitial lung disease. 13. a history of coagulopathy resulting in uncontrolled bleeding or other bleeding disorders. 14. participated in a clinical study of an investigational agent within 30 days of screening. 15. has known psychiatric, substance abuse, or other disorders that would interfere with cooperation with the requirements of the study in the opinion of the investigator. 16. is pregnant or breastfeeding.
extracorporeal shock wave therapy versus manual lymphatic drainageon cellulite post liposuction

Conditions: Cellulite

Summary: to determine whether extracorporeal shock wave therapy (eswt) or manual lymphatic drainage (mld) is more effective for decreasing post-liposuction cellulite. thirty females with grade 3 cellulite were randomly distributed into two equal groups: group a (eswt group) (n=15) and group b (mld group) (n=15). the cellulite grade was assessed by using the cellulite grading scale, and the thickness of subcutaneous fat was assessed by the skinfold caliper. the assessment was carried out before starting the treatment and after 4 weeks. all participants received treatment 2 times/ week for 4 weeks.


Eligibility criteria:
inclusion criteria: * female patients * age ranged from 25-45 years old, * non- pregnant females * grade 3 cellulite at thigh area after liposuction exclusion criteria: * breastfeeding females * inflammatory skin disorders in the treatment area * edema * varicose veins- * any therapy or disease that may affect treatment
continuous heart rate variability monitoring in doctors; understanding patterns of stress and recovery and their relationship with self-reported resilience, burnout and wellbeing.

Conditions: Burnout; Burnout Syndrome; Occupational Stress; Stress

Summary: burnout is an increasing concern in the medical professions. this study aims to utilise established, validated self-report measures combined with continuous heart rate variability measurements to better understand the stress and recovery patterns experienced by doctors that may contribute to burnout. this mixed methods study design will consist of an ecological momentary assessment phase where participants will complete commonly used and validated real-time subjective measures while concurrently wearing a heart rate variability monitor to provide an objective measure of stress. following on from this, participants of interest will be invited to participate in semi structured interviews to further explore their experiences of stress and recovery.


Eligibility criteria:
inclusion criteria: * working within nhs grampian * access to a smartphone exclusion criteria: * cardiac arrhythmias/endocrine disease. * prescription beta blockers, calcium channel blockers, ace inhibitors, benzodiazepines, antidepressants and antianxiety medications. * insufficient non-working time prior to study commencement.

Keywords: heart rate variability hrv occupational stress resilience fatigue wellbeing stress burnout
new thyroid fine needle aspiration biopsy apparatus

Conditions: Thyroid Cancer

Summary: evaluation of the effectivity of the new thyroid fine needle aspiration biopsy (fnab) apparatus of which patented from turkish patent institute.

the author group of this investigation produced a new thyroid fine needle aspiration biopsy (fnab) apparatus and patented it from turkish patent institute. fnab indicated nodular goitre patients are the subjects of this research. first, the investigators will perform standart fnab after this procedure will perform fnab with new apparatus. the investigators will evaluate the aspirates according to number of cells and malignity ratio of cells.

Eligibility criteria:
inclusion criteria: * fine needle aspiration biopsy indicated noduler goiter patients exclusion criteria: * diffuse goiter

Keywords: thyroid fine needle aspiration biopsy new technique
assessing the impact of covid-19 on hmpv incidence and severity among adults

Conditions: The Prevalance of HMPV After COVID-19 Pandemic; The Importance of Accurate Diagnosis for HPMV

Summary: human metapneumovirus (hmpv) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. this study investigates the prevalence, clinical characteristics, and post-covid-19 trends of hmpv infection among adults in istanbul, turkey.

human metapneumovirus (hmpv) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. this study investigates the prevalence, clinical characteristics, and post-covid-19 trends of hmpv infection among adults in istanbul, turkey.

Eligibility criteria:
inclusion criteria: * adults \>18 years * patients with acute respiratory tract infection symptoms * patients who underwent multiplex pcr testing for respiratory viruses exclusion criteria: * patients for whom no respiratory viral panel test was conducted

Keywords: adults human metapneumovirus post-covid-19 era prevalence underestimated virus
impact of donor-specific antibodies in (highly-) immunized living donor kidney transplant recipients

Conditions: Renal Failure

Summary: kidney transplantation is the preferred treatment for end-stage renal disease. alongside limited availability of donors, rejection and premature graft loss are main barriers to kidney transplantation. donor-specific antibodies pre-transplantation may arise due to to prior solid organ transplantation, pregnancy or blood transfusions. their presence is considered a risk of graft failure. the impact of dsa is differently reported in literature, also according to the technique by which dsa have been measured. techniques such as the complement-dependent cytotoxicity crossmatch, the immunofluorescence crossmatch and the luminex single antigen bead have different sensitivities for detecting dsa. historically, our kidney transplant program has been advocating living donor transplantation and as a result the majority of transplantations are with a living donor. in this context and in the absence of a compatible living donor, pretransplant dsa have not been considered an absolute contra-indication for transplantation. the aim of the current study is to determine the effect of dsas on rejection and death-censored graft survival in living donor kidney transplantation. participants are adults who underwent a living donor kidney transplantation between 2010 and 2019 in the presence of dsa. control subjects are both immunized and non-immunized kidney transplant recipients in the same period. this is a retrospective, case control study. death-censored graft survival is analyzed for all patients and compared by presence of dsa and other predicting variables, such as immunization level, age, sex and hla mismatches. furthermore, biopsy proven rejection, patient survival, kidney function, length of hospital stay and proteinuria are analyzed. also, a predefined subgroup analysis is performed in the dsa positive patients. these are compared according to amount, strength and hla-class of dsas.


Eligibility criteria:
inclusion criteria: * pre-transplantation donor-specific antibodies in luminex single antigen bead analysis. * age 18 years or older exclusion criteria: * desensitization treatment for a current or historic positive cdc-crossamtch
evaluation of the application of pegylated recombinant human granulocyte stimulating factor injection (peg-rhg-csf) in chemotherapy of elderly lymphoma patients

Conditions: Elderly Lymphoma Patients

Summary: a multicenter, open, one-arm clinical study evaluated the efficacy and safety of jinyouli in preventing neutropenia after chemotherapy in elderly lymphoma patients who met the criteria for admission. chemotherapy regimen: the investigator selected according to the specific condition the corresponding standard chemotherapy regimen, the chemotherapy regimen used, fn risk ≥ 20%, or 10% \< fn risk \< 20% with at least one high risk factor for fn, from the first cycle of chemotherapy, 24-72 after chemotherapy hour subcutaneous injection of jinyouli.


Eligibility criteria:
inclusion criteria: * (1) age ≥ 65 years, gender is not limited; * (2) patients with lymphoma diagnosed by histopathology or cytology; * (3) patients requiring multi-cycle chemotherapy; * (4) planned chemotherapy regimen fn risk ≥ 20 % (see annex i), or 10% \<fn risk \< 20% (see annex ii) with high risk factors for at least one fn; * (5) physical status (kps) score ≥ 70 points; * (6) expected survival period of more than 3 months; * (7) normal bone marrow hematopoietic function (anc ≥1.5×109/l, plt≥100×109/l, hb≥80g/l, wbc≥3.0×109/l); * (8) the testers (or their legal representatives/guardians) must sign an informed consent form. exclusion criteria: * (1) lymphoma central involvement; * (2) hematopoietic stem cell transplantation or organ transplantation; * (3) insufficient local or systemic infection; * (4) severe internal organ dysfunction and occurred in the last 6 months myocardial infarction; * (5) liver function tests total bilirubin (tbil), alanine aminotransferase (alt), and aspartate aminotransferase (ast) are \>2.5 times the upper limit of normal, if the above indicators are \>5 times due to liver metastasis upper limit of normal value; renal function test: serum creatinine (cr) \> 2 times the upper limit of normal; * (6) allergic to peg-rhg-csf, rhg-csf and other preparations or proteins expressed by escherichia coli; * (7) severe mental illness, affecting informed consent and/or adverse reaction expression or observation; * (8) the investigator judges patients who are not suitable for participation.

Keywords: peg-rhg-csf
trauma as a trigger for autoimmunity

Conditions: Autoimmunity

Summary: to analyse the immunological reaction to trauma (pertrochanteric femoral fracture with consequent osteosynthesis) in the first weeks up to one year postoperatively with focus on the development of autoimmunity.

this project represents a unique study of the influence of trauma on the immune system. it addresses the question whether an excess of apoptotic/necrotic cells can induce an at least transient autoimmune phenomena in humans. if the hypothesis of a transient induction of autoimmunity by trauma proves to be correct, this study will provide a novel insight into the pathogenesis of autoimmune diseases.

Eligibility criteria:
inclusion criteria: * pertrochanteric femoral fracture (≤7 days) * planned gamma nail osteosynthesis * ability to give written informed consent exclusion criteria: * severe hepatic and renal failure * current active oncological disease * current immunosuppressive or biological therapy * known systemic autoimmune disease * foreseeable lack of complete follow-up (e.g. due to generally poor health) * cognitive impairment (delirium, dementia, alteration of consciousness) * insufficient knowledge of project language * pregnancy

Keywords: trauma immunological reaction to trauma pertrochanteric femoral fracture antinuclear antibodies activation of innate immunity adaptive immunity
efficacy and safety of intraparenchymal portal vein covered stents in treating portal hypertension and its complications

Conditions: Portal Hypertension

Summary: the objective of this study is to assess the non-inferiority of the intraparenchymal portal vein covered stent in terms of safety and efficacy for managing portal hypertension and its related complications, in comparison to the currently available tips covered stent system by gore.

this study is a prospective, multicenter, randomized controlled, non-inferiority clinical trial. it plans to enroll approximately 258 qualified participants from about 25 research centers nationwide. participants will be randomly assigned in a 1:1 ratio to either the experimental group or the control group for the treatment of portal hypertension and its related complications. the primary endpoint of the study is the patency rate of the stents 12 months after the initial surgery. all participants will undergo clinical follow-ups at 1 month, 6 months, and 1 year post-stent implantation.

Eligibility criteria:
inclusion criteria: * age 18-75 years (inclusive); male or non-pregnant female. * diagnosed with cirrhosis and associated complications of portal hypertension (such as esophageal and gastric variceal bleeding, refractory ascites), and meeting the consensus recommendations for tips indications (see appendix 5). * participants must understand the purpose of the trial, voluntarily participate, sign an informed consent form, and be willing to complete the follow-up according to the project requirements. exclusion criteria: * severe right heart failure, congestive heart failure (lvef \< 40%), or severe valvular heart dysfunction. * uncontrolled systemic infection or inflammation. * persistent moderate to severe pulmonary hypertension after treatment (tricuspid regurgitant peak velocity \> 3.4 m/s or pulmonary artery systolic pressure \> 50 mmhg). * patients in hepatic encephalopathy coma or comatose phase (west haven criteria stage iii, iv). * severe liver dysfunction, child-pugh score \> 13, or meld score \> 18. * serum creatinine (scr) \> 178 umol/l or on dialysis. * stage iiia or higher liver malignancy. * budd-chiari syndrome, hepatic veno-occlusive disease, or obstructive cholestasis. * polycystic liver disease. * unrectifiable coagulopathy (inr \> 5 or plt count \< 20 x 10\^9/l). * main portal vein thrombosis occupying \> 50% of the lumen area or cavernous transformation of the portal vein. * previous tips procedure or planned liver transplantation within a year. * allergy to contrast agents or nickel-titanium alloys. * life expectancy less than 1 year. * participation in other drug or medical device clinical trials within three months before screening. * other conditions deemed by the researcher as unsuitable for participation in this clinical trial.

Keywords: portal hypertension
sleeve gastrectomy with jejuno-ileal bypass versus single anastomosis sleeve jejunal bypass

Conditions: Obesity, Morbid

Summary: sleeve gastrectomy with jejunoileal bypass (sgjib) is a novel technique for the surgical treatment of obesity. the aim of the study is to compare this maneuver with single anastomosis sleeve jejunal bypass (sas-jb)

200 patients will be randomly divided into to equal . group 1 will be operated by sleeve gastrectomy with jejunoileal bypass with the anastomosis between the jejunum at about 100 cm from the duodeno-jejunal flexure and the ileum at 250 cm from the ileocaecal junction. and group 2 will be operated by single anastomosis sleeve jejunal bypass (sas-jb) with biliary limb equal one third of total intestinal length.

Eligibility criteria:
inclusion criteria: * obese patients with bmi more than 40 with or without co-morbidity or more than 35 with co-morbidity * patients fit for laparoscopic surgery * give approval to share in the study exclusion criteria: * patients refused to share in the study * patients unfit for surgery * patients aged less than 18 and older than 60 * patient with previous upper abdominal surgery either for obesity or other diseases * revisional bariatric procedures